Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral oncolysis.

John T Mullen1, Kenneth K Tanabe

  • 1Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114-2696, USA.

The Oncologist
|April 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CD49b (ITGA2) collagen receptor excludes CD8<sup>+</sup> T cell infiltration in pancreatic ductal adenocarcinoma.

iScience·2026
Same author

Phase 1 trial of pre-operative image guided intensity modulated photon radiotherapy with simultaneously integrated boost to the high-risk margin for patients with retroperitoneal sarcoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Single-cell transcriptomics reveals the impact of sex and age in the healthy human liver.

JHEP reports : innovation in hepatology·2026
Same author

Neoadjuvant stereotactic body radiation therapy plus immune therapy favorably remodels the hepatocellular carcinoma tumor microenvironment.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Correction: Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram.

Frontiers in oncology·2026
Same author

High-speed wide-field fluorescence lifetime imaging for intraoperative tumor visualization and in vivo multiplexing.

Biomedical optics express·2025
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
See all related articles

Genetically engineered oncolytic viruses offer potent, tumor-specific cancer treatment. These viruses leverage viral functions and immune responses to enhance antineoplastic efficacy, with several in clinical trials.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Replicating viruses have long been considered for cancer treatment.
  • Genetic modification has enhanced the potency and tumor specificity of viral vectors.
  • Understanding viral gene functions is key to improving anticancer efficacy.

Purpose of the Study:

  • To review the mechanisms of oncolytic virus antitumor efficacy and specificity.
  • To discuss the dual role of the immune response in oncolytic viral therapy.
  • To examine commonly used oncolytic viruses and their clinical trial status.

Main Methods:

  • Review of general mechanisms of oncolytic virus action.
  • Analysis of viral gene product functions in cell cycle control and defense evasion.

Related Experiment Videos

  • Examination of the immune response's paradoxical roles in oncolytic therapy.
  • Review of specific oncolytic viruses: adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, and Newcastle disease viruses.

    • Main Results:

    • Oncolytic viruses achieve antitumor effects through enhanced viral functions and specificity.
    • The immune system can both hinder viral spread and promote tumor cell destruction.
    • Different oncolytic viruses (adenoviruses, HSV, vaccinia, reoviruses, NDV) possess unique biological properties.
    • Several oncolytic virus mutants are currently undergoing clinical evaluation.

    Conclusions:

    • Genetically modified oncolytic viruses represent a promising cancer therapy approach.
    • Optimizing viral functions and understanding immune interactions are crucial for efficacy.
    • Ongoing clinical trials are evaluating the therapeutic potential of various oncolytic viruses.